September 18, 2025

Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC

Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB NSCLC, based on the prim...

The ASCO Post

September 18, 2025

CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

“Maintaining quality of life during and after treatment is vital to long-term success, and these results show that perioperative nivolumab supports both survival and patient well-being,” said experts ...

The ASCO Post

September 18, 2025

Observation Outperforms Adjuvant Crizotinib for Resected ALK-Positive NSCLC

Adjuvant treatment with the first-generation ALK inhibitor crizotinib failed to improve disease-free survival outcomes over observation for patients with surgically resected ALK-positive non–small cel...

The ASCO Post

September 15, 2025

Is IFITM3 a Driver of Immunotherapy Response in SCLC?

New research has identified interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in SCLC, offering a promising new avenue for overcoming resistance ...

The ASCO Post

September 15, 2025

Tarlatamab and Anti–PD-1 Therapy as First-Line Maintenance for ES-SCLC

The DLL3-targeted bispecific T-cell engager agent tarlatamab demonstrated significant overall survival in combination with anti‒PD-L1 therapy of either atezolizumab or durvalumab as first-line mainten...

The ASCO Post

September 10, 2025

Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options

ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently....

The ASCO Post

September 03, 2025

Temple Lung Center Performs First U.S. BREATHE-3 Procedure for Severe Emphysema

The Phase-3 trial of Apreo Health’s bronchoscopic airway scaffold for severe emphysema and hyperinflation is now enrolling at the Temple Lung Center.

Temple Health

September 03, 2025

Inhaler Cataract Risk

Childhood asthma and inhaled corticosteroids linked to increased cataract risk in adulthood, says Danish study

The Ophthalmologist

August 22, 2025

Personalizing First-Line Therapy in NSCLC: Plasma-Guided Adaptive Treatment Approach

In patients with newly diagnosed, PD-L1–positive, advanced non–small cell lung cancer (NSCLC) who tested negative for driver mutations, implementation of plasma-guided treatment intensification—from m...

The ASCO Post